\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.1.1}{Emergence of antibiotic resistance}{chapter.1}% 2
\BOOKMARK [1][-]{section.1.2}{\337-lactams}{chapter.1}% 3
\BOOKMARK [2][-]{subsection.1.2.1}{Cephalosporins}{section.1.2}% 4
\BOOKMARK [1][-]{section.1.3}{Resistance mechanisms}{chapter.1}% 5
\BOOKMARK [2][-]{subsection.1.3.1}{Resistance to \337-lactams}{section.1.3}% 6
\BOOKMARK [1][-]{section.1.4}{ESBL E. coli}{chapter.1}% 7
\BOOKMARK [2][-]{subsection.1.4.1}{Identification of ESBL E. coli and treatment}{section.1.4}% 8
\BOOKMARK [1][-]{section.1.5}{Identifying mutations predicting cefepime resistance of ESBL E. coli}{chapter.1}% 9
\BOOKMARK [2][-]{subsection.1.5.1}{Principles of the morbidostat}{section.1.5}% 10
\BOOKMARK [2][-]{subsection.1.5.2}{Previous morbidostat experiments and expected outcome}{section.1.5}% 11
\BOOKMARK [2][-]{subsection.1.5.3}{Illumina and Nanopore sequencing}{section.1.5}% 12
\BOOKMARK [1][-]{section.1.6}{Aim of this thesis}{chapter.1}% 13
\BOOKMARK [0][-]{chapter.2}{Materials and methods}{}% 14
\BOOKMARK [1][-]{section.2.1}{ESBL E. coli isolates sampled from patients at the University Hospital of Basel}{chapter.2}% 15
\BOOKMARK [2][-]{subsection.2.1.1}{Disk diffusion tests}{section.2.1}% 16
\BOOKMARK [2][-]{subsection.2.1.2}{MIC determination}{section.2.1}% 17
\BOOKMARK [2][-]{subsection.2.1.3}{Selection of isolates suitable for our analysis}{section.2.1}% 18
\BOOKMARK [2][-]{subsection.2.1.4}{Identification of SNPs}{section.2.1}% 19
\BOOKMARK [2][-]{subsection.2.1.5}{Studying copy numbers of ESBL genes}{section.2.1}% 20
\BOOKMARK [1][-]{section.2.2}{Bioinformatic pipeline for identifying SNPs in resistant ESBL E. coli}{chapter.2}% 21
\BOOKMARK [2][-]{subsection.2.2.1}{Creating a reference genome with annotation}{section.2.2}% 22
\BOOKMARK [2][-]{subsection.2.2.2}{Mapping Illumina sequencing data of the isolate series to the reference genome}{section.2.2}% 23
\BOOKMARK [2][-]{subsection.2.2.3}{Calculating pile-ups}{section.2.2}% 24
\BOOKMARK [2][-]{subsection.2.2.4}{Identification of SNPs}{section.2.2}% 25
\BOOKMARK [2][-]{subsection.2.2.5}{Identifying genes and promoters affected by SNPs}{section.2.2}% 26
\BOOKMARK [1][-]{section.2.3}{Assembling the morbidostat}{chapter.2}% 27
\BOOKMARK [2][-]{subsection.2.3.1}{OD measuring units}{section.2.3}% 28
\BOOKMARK [2][-]{subsection.2.3.2}{Pumps and tubing}{section.2.3}% 29
\BOOKMARK [2][-]{subsection.2.3.3}{Controlling the morbidostat}{section.2.3}% 30
\BOOKMARK [2][-]{subsection.2.3.4}{Hardware calibration}{section.2.3}% 31
\BOOKMARK [1][-]{section.2.4}{Experimentally evolving resistance with the morbidostat}{chapter.2}% 32
\BOOKMARK [2][-]{subsection.2.4.1}{Gibson cloning}{section.2.4}% 33
\BOOKMARK [2][-]{subsection.2.4.2}{Culturing ESBL E. coli strains with the morbidostat}{section.2.4}% 34
\BOOKMARK [2][-]{subsection.2.4.3}{Analysis of the morbidostat samples}{section.2.4}% 35
\BOOKMARK [0][-]{chapter.3}{Results}{}% 36
\BOOKMARK [1][-]{section.3.1}{Identifying SNPs in ESBL E. coli isolates series with changing cefepime susceptibility}{chapter.3}% 37
\BOOKMARK [2][-]{subsection.3.1.1}{Selection of isolate series suitable for our analysis}{section.3.1}% 38
\BOOKMARK [2][-]{subsection.3.1.2}{Identification of SNPs in patient isolates}{section.3.1}% 39
\BOOKMARK [2][-]{subsection.3.1.3}{Copy numbers of ESBL genes}{section.3.1}% 40
\BOOKMARK [1][-]{section.3.2}{Morbidostat experiments}{chapter.3}% 41
\BOOKMARK [2][-]{subsection.3.2.1}{Contamination analysis}{section.3.2}% 42
\BOOKMARK [2][-]{subsection.3.2.2}{Growth curves and injected concentrations}{section.3.2}% 43
\BOOKMARK [2][-]{subsection.3.2.3}{MIC of the strains used for culturing with the morbidostat}{section.3.2}% 44
\BOOKMARK [2][-]{subsection.3.2.4}{SNPs of experiment 01}{section.3.2}% 45
\BOOKMARK [2][-]{subsection.3.2.5}{SNPs of experiment 02}{section.3.2}% 46
\BOOKMARK [0][-]{chapter.4}{Discussion}{}% 47
\BOOKMARK [1][-]{section.4.1}{Technical and experimental challenges with the morbidostat}{chapter.4}% 48
\BOOKMARK [2][-]{subsection.4.1.1}{Hardware issues}{section.4.1}% 49
\BOOKMARK [2][-]{subsection.4.1.2}{Software issues}{section.4.1}% 50
\BOOKMARK [2][-]{subsection.4.1.3}{Bacillus cereus contamination of the morbidostat experiments}{section.4.1}% 51
\BOOKMARK [1][-]{section.4.2}{Bioinformatic challenges}{chapter.4}% 52
\BOOKMARK [1][-]{section.4.3}{Culturing with the morbidostat}{chapter.4}% 53
\BOOKMARK [1][-]{section.4.4}{Potential resistance mechanisms considering mutated operons}{chapter.4}% 54
\BOOKMARK [2][-]{subsection.4.4.1}{SNPs in porin operons}{section.4.4}% 55
\BOOKMARK [2][-]{subsection.4.4.2}{SNPs in the transcription machinery operon}{section.4.4}% 56
\BOOKMARK [2][-]{subsection.4.4.3}{SNPs affecting other operons}{section.4.4}% 57
\BOOKMARK [1][-]{section.4.5}{Conclusion}{chapter.4}% 58
\BOOKMARK [1][-]{section.4.6}{Outlook}{chapter.4}% 59
\BOOKMARK [0][-]{chapter.5}{Supplementary}{}% 60
\BOOKMARK [1][-]{section.5.1}{Manual for the software control of the morbidostat}{chapter.5}% 61
\BOOKMARK [2][-]{subsection.5.1.1}{Manually turning on pumps of the morbidostat}{section.5.1}% 62
\BOOKMARK [2][-]{subsection.5.1.2}{Staring morbidostat experiments}{section.5.1}% 63
\BOOKMARK [1][-]{section.5.2}{Gibson cloning}{chapter.5}% 64
\BOOKMARK [2][-]{subsection.5.2.1}{Sequences of fragments}{section.5.2}% 65
\BOOKMARK [0][-]{chapter.6}{References}{}% 66
